


## ABSTRACT

This invention provides: a pharmaceutical composition for use in cancer treatment comprising, as an active ingredient, a compound represented by the following formula I:



wherein  $\text{X}^1\text{-CHR}^1\text{-O-CO-NR}^2$  represents a linker,  $\text{X}^1$  represents a spacer,  $\text{R}^1$  represents a C1-C4 alkyl group that may be substituted,  $\text{R}^2$  represents a phenyl group or a substituted phenyl group,  $\text{X}^2$  represents SN-38, and  $n$  is an integer of 200 to 1,000, and wherein the pharmaceutical composition is usable with administration and dosage in which a single dose of about 0.01  $\mu\text{mol/kg}$  body weight to about 11  $\mu\text{mol/kg}$  body weight is parenterally administered to a subject having cancer at a frequency of once a week, every other week over at least 2 weeks, and has no Irinotecan-like side effects and provides cancer growth inhibiting activity equivalent to or larger than that of Irinotecan when used at a dose as low as 1/10 (in a molar ratio) or less as compared with Irinotecan; and a method for treating a cancer using the composition.